Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Analytical Biochemistry|May 2, 2006
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxinDiana V Pastrana, David J FitzGeraldInternational Journal of Cancer|July 24, 2012
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell linesAbid R Mattoo, David J FitzGeraldMolecular Cancer Therapeutics|April 18, 2014
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxinAntonella Antignani, Robert Sarnovsky, David J FitzGeraldCancer Research|January 26, 2013
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxinXiu Fen Liu, David J FitzGerald, Ira PastanFrontiers in Immunology|November 7, 2022
Managing the TME to improve the efficacy of cancer therapyMaria Teresa Bilotta, Antonella Antignani, David J FitzgeraldJournal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cellsKevin Hollevoet, Antonella Antignani, David J Fitzgerald, et al.Cancer Research|August 5, 2008
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activityXing Du, Richard Beers, David J Fitzgerald, et al.Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.Molecular Cancer Therapeutics|October 23, 2013
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitorsXiu-Fen Liu, Laiman Xiang, David J FitzGerald, et al.Pageof 5